Category: Inflammatory

Prime Therapeutics’ Studies Examine Rheumatoid Arthritis Therapies and Total Cost

ST. PAUL, Minn., Oct. 17, 2017 /PRNewswire/ — Two new studies by pharmacy benefit manager Prime Therapeutics LLC (Prime) show commercially insured members with rheumatoid arthritis (RA) had 3.5 times higher total cost of care than members without RA. But optimizing conventional disease…

Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array’s proprietary platform that leverages Array’s expertise in chemistry and early lead development.

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be used on the NHS for the treatment of severe active forms of the disease which has not responded to intensive therapy with conventional disease-modifying antirheumatic drugs (DMARDs), it has emerged.
read more